Patent ID: 9650444
Date: 2017-05-16
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method of blocking monomeric human platelet derived growth factor receptor beta (PDGFR-beta) signaling in a subject, comprising: administering to the subject a pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof that specifically binds (PDGFR-beta) with a binding dissociation equilibrium constant (K wherein the isolated antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) comprising SEQ ID NOs: 132, 134 and 136, respectively; and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising SEQ ID NOs: 140, 142 and 144, respectively.